Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Kurtin

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Cancer Chemotherapy and Pharmacology|July 19, 2006
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancerTomislav Dragovich, David Mendelson, Sandra Kurtin, et al.
Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique|February 1, 2013
Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nursesCindy Murray, Annie Wereley, Shannon Nixon, et al.
Journal of the Advanced Practitioner in Oncology|July 18, 2014
Nurse self-evaluation of assessment of chemotherapy-induced peripheral neuropathy in patients with cancerConstance Visovsky, Marilyn Haas, Beth Faiman, et al.
International Journal of Clinical Oncology|October 12, 2012
Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphomaDaruka Mahadevan, Donald W Northfelt, Pavani Chalasani, et al.
Expert Opinion on Pharmacotherapy|May 10, 2023
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapyPrithviraj Bose, Andrew T Kuykendall, Carole Miller, et al.
Cancer Medicine|April 28, 2016
Lack of health maintenance examinations and risk in myeloma patientsJoseph D Tariman, Charise Gleason, Beth Faiman, et al.
Patient Education and Counseling|May 12, 2019
Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignanciesThomas W LeBlanc, Walter F Baile, Susan Eggly, et al.
Leukemia & Lymphoma|October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinateLuke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Translational Behavioral Medicine|January 23, 2023
Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myelomaCarma L Bylund, Susan Eggly, Thomas W LeBlanc, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 11, 2010
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study groupMario E Lacouture, Michael L Maitland, Siegfried Segaert, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer Chemotherapy and Pharmacology|July 19, 2006
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancerTomislav Dragovich, David Mendelson, Sandra Kurtin, et al.
Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique|February 1, 2013
Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nursesCindy Murray, Annie Wereley, Shannon Nixon, et al.
Journal of the Advanced Practitioner in Oncology|July 18, 2014
Nurse self-evaluation of assessment of chemotherapy-induced peripheral neuropathy in patients with cancerConstance Visovsky, Marilyn Haas, Beth Faiman, et al.
International Journal of Clinical Oncology|October 12, 2012
Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphomaDaruka Mahadevan, Donald W Northfelt, Pavani Chalasani, et al.
Expert Opinion on Pharmacotherapy|May 10, 2023
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapyPrithviraj Bose, Andrew T Kuykendall, Carole Miller, et al.
Cancer Medicine|April 28, 2016
Lack of health maintenance examinations and risk in myeloma patientsJoseph D Tariman, Charise Gleason, Beth Faiman, et al.
Patient Education and Counseling|May 12, 2019
Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignanciesThomas W LeBlanc, Walter F Baile, Susan Eggly, et al.
Leukemia & Lymphoma|October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinateLuke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Translational Behavioral Medicine|January 23, 2023
Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myelomaCarma L Bylund, Susan Eggly, Thomas W LeBlanc, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 11, 2010
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study groupMario E Lacouture, Michael L Maitland, Siegfried Segaert, et al.
Pageof 3